Cancer Research UK | October 2019 | Targeted breast cancer treatment approved for NHS use in England
A new treatment for early stage breast cancer will be made available for certain patients on the NHS in England.
Following the recommendation from the National Institute for Health and Care Excellence (NICE), neratinib (Nerlynx) will be offered as an extended treatment for breast cancer patients who’ve had another targeted treatment, trastuzumab (Herceptin), within the last year.
The new treatment is said to “significantly reduce the proportion of breast cancer relapses”, according to short-term trial data.
Neratinib blocks the cancer growth by interfering with chemical signals sent between cells.
It’s recommended for use for patients whose cancer tests positive for hormone receptors and a molecule called HER2. The treatment will only be available to adults who’ve been treated with trastuzumab within the last year, and where trastuzumab was used after initial treatment to help stop their cancer coming back.
This is the first treatment available for patients who have previously taken trastuzumab that maintain the intended effect of that treatment (adjuvant therapy).
Further criteria which patients will have to meet in order to access the drug include:
- Trastuzumab is the only treatment they’ve taken that targets the molecule HER2
- If trastuzumab was given before surgery, there were still signs of cancer in the tissue samples removed during surgery (Source: Cancer Research UK)
Read the press release from Cancer Research UK
Full details available from NICE